Knowles Julius
SEC Form 4 insider trading activity
Knowles Julius has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jun 8, 2026.
On the most recent filing, Knowles Julius is listed as Director at Keros Therapeutics, Inc. Inside the rolling window, Knowles Julius reported no open-market purchases and 1 open-market sale totaling $28K in KROS.
Companies traded
Other insiders at KROS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$28K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Knowles Julius made?
Knowles Julius has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Knowles Julius trade?
Knowles Julius has filed SEC Form 4 disclosures for 1 company, including KROS.
When was Knowles Julius's most recent SEC Form 4 filing?
Knowles Julius's most recent SEC Form 4 filing on Tracefour is dated Jun 8, 2026.
What is Knowles Julius's total buy and sell value in the current window?
Inside the rolling retention window, Knowles Julius bought $0 and sold $28K based on SEC Form 4 filings.
What was Knowles Julius's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,625 KROS shares on 2026-06-04, worth $28K, per SEC Form 4 filings.